(AMRN) Amarin Corporation plc VRIO Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AMRN) Amarin Corporation plc Complete Analysis Pack
Amarin VRIO Analysis: Competitive Advantage, Sustainability, and Strategic Insight
Unlock Amarin Corporation plc’s competitive DNA with the full VRIO Analysis—an actionable breakdown of which resources and capabilities create real advantage, how sustainable they are, and where the company can outperform peers; ideal for analysts, investors, and strategists seeking a ready-to-use Word and Excel toolkit for deeper insight.
VASCEPA brand equity and prescriber familiarity
Value
In 2025, VASCEPA’s 4 g/day prescription format and established CV-risk data keep it top-of-mind for clinicians, so Amarin Corporation plc can preserve brand recall in a crowded omega-3 class. That familiarity supports steady pull-through in wholesaler and specialty-pharmacy channels, where repeat prescribing matters most.
Rarity
VASCEPA is relatively rare because few Company Name peers own a pharma-grade EPA-only asset with its long U.S. launch history since 2012 and the REDUCE-IT outcomes legacy, which keeps prescribers familiar with its profile. That familiarity matters in a market with only 1 branded EPA leader and limited true analogs.
Imitability
Rivals can run their own trials, but not fast or cheap: VASCEPA’s moat rests on years of clinical evidence, including REDUCE-IT’s 8,179-patient design and its 2019 cardiovascular label expansion. That history gives Amarin strong prescriber familiarity, and it makes imitation expensive because rivals must still prove the same outcomes, not just copy the molecule.
Organization
VASCEPA gives Amarin strong brand equity and prescriber familiarity, which lowers selling friction and supports repeat use in cardiometabolic care. Amarin also has the regulatory and compliance setup to operate across multiple jurisdictions, a key edge in a market where approval, labeling, and pharmacovigilance rules can change by country.
Competitive Advantage
VASCEPA has solid brand recognition among cardiology and primary care prescribers, but that familiarity has not translated into a durable moat. In Amarin Corporation plc’s 2025 context, the brand still faces competitive parity because prescribing can shift to lower-cost omega-3 alternatives and payer pressure limits pricing power.
VASCEPA’s REDUCE-IT Legacy Still Drives Prescriber Recall in 2025
In 2025, VASCEPA still had strong brand equity: Amarin Corporation plc’s REDUCE-IT legacy and 8,179-patient outcomes data keep prescribers familiar, especially in cardiology and primary care. That recall helps repeat prescribing, but payer pressure and omega-3 alternatives still cap pricing power.
| Metric | Data |
|---|---|
| REDUCE-IT | 8,179 patients |
| U.S. launch | 2012 |
| Label expansion | 2019 CV outcome |
What is included in the product
Detailed Word Document
A concise VRIO analysis of Amarin Corporation plc’s strategic resources, showing which capabilities are valuable, rare, hard to imitate, and well organized.
Customizable Excel Spreadsheet
Quickly reveals Amarin’s strategic resources, competitive edge, and defensibility without building a VRIO from scratch.
Reference Sources
Clarifies which Amarin resources are valuable, rare, costly to imitate, and organizationally supported to validate sustainable competitive advantage.
EPA-based intellectual property and formulation know-how
Value
Amarin Corporation plc’s EPA-only formulation and patent know-how support Vascepa’s 4 g/day prescription omega-3 position, which helps keep the brand distinct in a category crowded with mixed-oil products. That product recognition matters in wholesaler and specialty-pharmacy channels, where formulary pull and repeat scripts drive sell-through.
Rarity
Amarin Corporation plc’s EPA-based IP is relatively rare because few drug makers own a pharma-grade, EPA-only asset with this depth of clinical history. Vascepa is the only FDA-approved EPA-only prescription product, and its core evidence base includes REDUCE-IT, which enrolled 8,179 patients.
That track record makes the formulation know-how hard to copy, even for firms with omega-3 chemistry. In rarity terms, the asset stands out because it combines one approved EPA franchise, a long patent and regulatory trail, and real-world commercial proof, not just a lab recipe.
Imitability
Rivals can run EPA trials, but matching Amarin Corporation plc’s formulation know-how is slow and expensive. Its branded EPA drug, Vascepa, is protected by a patent estate that has been central to keeping generics out, so copycats face long clinical and regulatory lead times before they can compete.
Organization
Amarin’s EPA-based IP is reinforced by its regulatory and compliance setup, which supports operations across multiple jurisdictions. In its latest filings, Amarin’s global footprint spans the U.S. and Europe, and that scale makes quality systems, label control, and market-specific compliance part of the asset, not just a back-office cost.
Competitive Advantage
Amarin Corporation plc’s EPA-based IP and formulation know-how still supports Vascepa, but the moat is weaker now because core patents have faced generic challenges in major markets. That makes this capability a competitive parity factor: useful for defending share, but not enough to create a durable edge on its own.
Amarin’s EPA-Only Edge Still Matters, But the Moat Is Narrowing
Amarin Corporation plc’s EPA-only IP remains rare: Vascepa is still the only FDA-approved EPA-only prescription drug, and REDUCE-IT enrolled 8,179 patients. That formulation know-how helps defend the brand, but patent loss in key markets has made the moat narrower and closer to parity.
| Metric | Value |
|---|---|
| FDA-approved EPA-only product | 1 |
| REDUCE-IT patients | 8,179 |
Preview Before You Purchase
VRIO Analysis
The document you're previewing is the actual Amarin Corporation plc VRIO Analysis—not a mockup or sample—and it reflects the exact content and formatting you will receive after purchase; upon completion, you’ll get the full, ready-to-use file in Word and Excel formats for immediate editing, presentation, or sharing.
Clinical evidence and cardiovascular label
Value
Amarin Corporation plc’s cardiovascular label is valuable because REDUCE-IT cut major adverse cardiovascular events by 25% in 8,179 statin-treated patients, which keeps Vascepa recognized as a prescription omega-3 therapy. That proof of outcome benefit supports demand in wholesaler and specialty-pharmacy channels, where access and refill flow depend on clear clinical differentiation.
Rarity
Rarity is high because Amarin Corporation plc is one of very few firms with a pharma-grade EPA asset and a cardiovascular outcomes label. Vascepa remains the only FDA-approved, EPA-only omega-3 with a CV risk-reduction claim, backed by the REDUCE-IT trial’s 8,179 patients and 25% relative risk reduction in major CV events.
Imitability
Amarin Corporation plc’s cardiovascular label is hard to copy because it rests on REDUCE-IT, a 8,179-patient outcomes trial that drove a 25% relative risk cut in major adverse cardiovascular events. Rivals can run their own studies, but matching that evidence base takes years and very large budgets, so imitation is slow and expensive.
Organization
Amarin Corporation plc’s organization is built to handle strict regulatory work across the U.S. FDA and the European Medicines Agency, which matters because Vascepa is approved in both major markets. That compliance setup supports a multi-jurisdiction label, and Amarin reported 2024 net revenue of about $200 million, showing it can keep that regulatory engine active while managing a global product profile.
Competitive Advantage
Amarin Corporation plc’s clinical edge comes from REDUCE-IT, which showed a 25% relative reduction in major cardiovascular events and secured the Vascepa cardiovascular risk-reduction label. Still, this is now closer to competitive parity than a durable moat, because generic icosapent ethyl and wider statin-based prevention leave Amarin’s evidence strong but not exclusive.
Amarin’s REDUCE-IT Proof Still Supports Vascepa’s CV Edge
Amarin Corporation plc’s cardiovascular label still rests on REDUCE-IT, where 8,179 statin-treated patients saw a 25% relative cut in major adverse cardiovascular events. That FDA-backed outcomes proof keeps Vascepa differentiated, but the moat is narrower now because generic icosapent ethyl limits exclusivity.
| Metric | Data |
|---|---|
| REDUCE-IT | 8,179 patients |
| MACE reduction | 25% |
| Label | CV risk reduction |
Multi-market regulatory and commercial access
Value
Amarin Corporation plc’s multi-market regulatory and commercial access is valuable because it supports recognition for prescription omega-3 therapy and keeps demand moving through wholesaler and specialty-pharmacy channels. In 2024, net product revenue was about $230 million, and Vascepa remained the main driver across U.S. and ex-U.S. markets.
Rarity
Amarin Corporation plc’s pharma-grade EPA asset is relatively rare: Vascepa has held FDA approval since 2012 and EU approval since 2019, and few drug makers have a purified EPA franchise with this long regulatory record. That rarity supports multi-market access because it combines years of clinical and payer evidence with a brand already commercialized across major markets.
Imitability
Rivals can run omega-3 cardiovascular outcome trials, but they cannot copy Amarin Corporation plc’s evidence base quickly or cheaply: REDUCE-IT enrolled 8,179 patients and took years, while multi-market filings still require separate regulatory work in the US, Europe, and Asia. That makes imitation slow, costly, and commercially messy.
Organization
Amarin has the regulatory and compliance structure to sell across multiple jurisdictions, with a market-access model built around the U.S., Europe, and other approved regions. That breadth matters in VRIO terms because it supports fast filing, local compliance, and commercial launch discipline across more than one market.
Competitive Advantage
Amarin Corporation plc’s multi-market regulatory and commercial access is a competitive parity factor, not a moat: it has approvals and sales reach in the U.S. and multiple ex-U.S. markets, but rivals can still access similar cardiovascular channels and reimbursement paths. Its 2024 net product revenue was about $230 million, showing scale, yet not enough to turn broad access into a clear VRIO advantage.
Amarin’s Vascepa Access Is Real, But Not a Moat
Amarin Corporation plc’s multi-market regulatory and commercial access helps it keep Vascepa on pharmacy shelves in the U.S. and abroad, but it is still a parity factor, not a moat. In 2024, net product revenue was about $230 million, and the product’s FDA approval since 2012 plus EU approval since 2019 show real reach, not unique lock-in.
| Metric | Data |
|---|---|
| 2024 net product revenue | about $230 million |
| U.S. FDA approval | 2012 |
| EU approval | 2019 |
Wholesale and specialty-pharmacy distribution network
Value
Amarin Corporation plc’s wholesale and specialty-pharmacy network is valuable because it keeps Vascepa visible in the prescription omega-3 category and supports refill flow through the main U.S. drug channels; in 2024, Amarin said this product remained its core revenue driver. That broad channel reach helps sustain demand where access and formulary placement often decide whether patients stay on therapy.
Rarity
Amarin Corporation plc’s wholesale and specialty-pharmacy distribution network is relatively rare because very few companies own a pharma-grade EPA asset with this kind of long clinical and regulatory track record. In 2025, that same channel still matters because prescription omega-3 reach depends on managed access, and Amarin’s network helps keep VASCEPA/VAZKEPA in front of wholesalers and specialty pharmacies that serve high-value cardiometabolic patients.
Imitability
Rivals can run trials, but matching Amarin Corporation plc's wholesale and specialty-pharmacy links is slow and expensive. In 2025, specialty drugs still needed payer access, hub support, and contracting one deal at a time, while a single late-stage clinical program can burn tens of millions of dollars before launch.
Organization
Amarin’s wholesale and specialty-pharmacy network is organized to meet FDA, EMA, and country-level rules, which lets it move Vascepa/Vazkepa across several jurisdictions without breaking compliance. In its latest reported year, Amarin generated about $215 million in net revenue, and that scale depends on tight controls for licensing, cold-chain handling, and market-specific labeling.
Competitive Advantage
Amarin Corporation plc’s wholesale and specialty-pharmacy distribution network is a necessary channel, but it does not create clear VRIO advantage because rivals can access similar U.S. pharmacy and wholesaler routes. That leaves it at competitive parity, not a durable edge, unless the network lowers cost or speeds refill conversion better than peers.
Amarin’s pharma network supports sales—but it’s not a lasting moat
Amarin Corporation plc’s wholesale and specialty-pharmacy network still supports Vascepa access in the U.S. and abroad, but it is a standard pharma channel, not a hard-to-copy moat. In 2025, Amarin reported about $215 million in net revenue, showing the network helps cash flow, yet rivals can still reach similar wholesalers and specialty pharmacies.
| Metric | 2025 |
|---|---|
| Net revenue | about $215 million |
| VRIO view | competitive parity |
Cardiovascular commercial and medical-affairs know-how
Value
Amarin Corporation plc’s cardiovascular commercial and medical-affairs know-how is valuable because VASCEPA already has FDA-backed cardiovascular risk-reduction and severe hypertriglyceridemia labels, which helps sustain prescriber trust and demand across wholesaler and specialty-pharmacy channels. In 2024, Amarin reported net product revenue of about $200 million, showing this channel execution still matters.
Rarity
Amarin Corporation plc’s cardiovascular commercial and medical-affairs know-how is relatively rare because few firms control a pharma-grade EPA asset with this much history; Vascepa/icosapent ethyl was built on the 8,179-patient REDUCE-IT trial, a scale many peers never reach. That depth shows in execution, with 2025 net revenue of about $230 million, reflecting a niche but durable market position.
Imitability
Amarin Corporation plc’s cardiovascular commercial and medical-affairs know-how is hard to imitate because rivals can run trials, but not quickly or cheaply. REDUCE-IT enrolled 8,179 patients and showed a 25% relative risk reduction in major CV events, and large outcomes studies often take 5-7 years and more than $100 million, so copying the evidence base is slow and expensive.
Organization
Amarin’s organization is a strong VRIO asset because it supports VASCEPA/Icosapent Ethyl compliance and commercialization across the U.S. and Europe, where it manages one prescription drug and multi-market regulatory rules. That regulatory and medical-affairs setup helps it keep product, labeling, and pharmacovigilance controls aligned across jurisdictions, which is hard for smaller peers to copy.
Competitive Advantage
Amarin Corporation plc’s cardiovascular commercial and medical-affairs know-how is useful, but it is not rare, so it fits competitive parity rather than durable advantage. With Vascepa/Vazkepa still competing in a crowded omega-3 and cardiometabolic market after U.S. exclusivity ended in 2020, the edge comes from execution, not a unique capability.
Amarin’s commercial edge helps, but crowding limits its moat
Amarin Corporation plc’s cardiovascular commercial and medical-affairs know-how still matters because it supports VASCEPA/Vazkepa uptake, but it is not a lasting moat on its own. 2025 net product revenue was about $230 million, showing execution strength, yet the asset now competes in a crowded omega-3 market.
| Metric | 2025 |
|---|---|
| Net product revenue | about $230 million |
Mochida collaboration ecosystem
Value
Mochida collaboration helps Amarin keep Vascepa visible in prescription omega-3 therapy, supporting demand in wholesaler and specialty-pharmacy channels. In FY2025, this matters because Amarin still relies on commercial channel reach to offset U.S. net revenue pressure and protect branded volume.
Rarity
Amarin Corporation plc’s Mochida collaboration ecosystem is rare because very few companies own a pharma-grade EPA asset with this depth of development history; Vascepa, built on purified icosapent ethyl, won U.S. FDA approval in 2012 and a cardiovascular label expansion in 2019. That long, validated path makes the partnership harder to replicate than a standard licensing deal.
Imitability
Amarin Corporation plc’s Mochida collaboration ecosystem is hard to copy because rivals can fund trials, but they cannot do it quickly or cheaply. REDUCE-IT followed 8,179 patients for 4.9 years and drove a 25% lower major CV event risk, so matching that evidence base takes years and heavy spend.
Organization
Amarin’s organization is a real moat because it can run regulatory, quality, and pharmacovigilance work across the U.S. and Europe, where VAZKEPA is approved in 45 countries in Europe. That multi-jurisdiction setup cuts compliance risk and helps the Mochida collaboration move faster without losing control.
Competitive Advantage
Mochida’s collaboration ecosystem gives Amarin access to local Japan distribution and regulatory know-how, but the same kind of partner-led model is common in pharma, so it delivers competitive parity, not a lasting edge. In VRIO terms, the network is valuable and organized, yet it is not rare or hard to copy, so rivals can match it with similar licensing deals in 2025–2026.
Mochida Boosts Japan Access, but It’s Not a Moat
Mochida collaboration gives Amarin Corporation plc local Japan reach and regulatory support, but it is a standard pharma partnership, not a unique moat. In FY2025, the value is practical: it helps preserve Vascepa’s channel access while Amarin still faces U.S. net revenue pressure and depends on branded volume.
| VRIO factor | FY2025 view |
|---|---|
| Value | Supports Japan access |
| Rarity | Low |
| Imitability | Easy to copy |
| Organization | Partner-led and usable |
Asset-light supply chain and manufacturing management
Value
Amarin Corporation plc’s asset-light supply chain keeps fixed manufacturing spend low, so more cash can go to commercial pull for Vascepa, the prescription omega-3 brand. That helps preserve recognition and refill flow in wholesaler and specialty-pharmacy channels, even as the company relies on outsourced production and distribution rather than owned plants.
Rarity
Amarin Corporation plc is relatively rare because it owns Vascepa, the only FDA-approved prescription EPA product in the U.S., and that pharma-grade asset has a long commercial and regulatory history that few rivals can match. In FY2025, Amarin still reported a standalone specialty pharma model built around this single EPA platform, which makes its supply-chain and manufacturing setup unusual in the market.
Imitability
Amarin Corporation plc’s asset-light supply chain and manufacturing model is only moderately hard to copy: rivals can run their own trials, but Phase 3 studies often take 2 to 5 years and can cost $20 million to $100 million, so fast imitation is rare. Even then, they still need validated supply, quality control, and regulatory execution, which slows direct replication.
Organization
Amarin’s organization supports an asset-light model by using a tight regulatory and compliance setup that can handle multiple jurisdictions, from the U.S. FDA to EU and other market rules. This lets the Company keep manufacturing and distribution flexible while staying compliant across more than one operating region.
Competitive Advantage
Amarin Corporation plc’s asset-light supply chain and manufacturing setup is a cost-control choice, not a durable moat. Because it relies on third-party manufacturing and logistics, the structure is easy for peers to match, so this area supports competitive parity rather than sustained advantage.
Amarin’s Lean Supply Chain Keeps Cash Focused on Vascepa
Amarin Corporation plc’s asset-light supply chain keeps fixed plant costs near zero, so FY2025 cash can stay focused on Vascepa commercialization, not factories. It is easy to copy in form, but hard to match in execution because the Company still needs compliant third-party manufacturing and cross-border quality control for its one EPA product.
| Metric | FY2025 |
|---|---|
| Owned manufacturing | 0 plants |
| FDA-approved EPA products | 1 |
Focused capital allocation and lean operating model
Value
Amarin Corporation plc’s focused capital allocation and lean operating model keep spend tied to VASCEPA awareness and channel support, which helps preserve prescription omega-3 recognition in wholesalers and specialty pharmacies. That matters because a slim cost base lets the Company defend demand without heavy overhead, a key advantage in a market where small changes in refill volume can move revenue fast.
Rarity
Amarin Corporation plc’s capital is tightly focused on one pharma-grade EPA asset, Vascepa, and that long clinical and regulatory history is rare in omega-3 pharma. In 2025, that single-asset model stayed lean, with R&D and SG&A kept narrow versus diversified drug makers, which helps preserve cash and makes the asset more distinctive.
Imitability
Rivals can fund trials, but they cannot copy Amarin Corporation plc’s speed or low-cost model easily; late-stage cardiovascular outcomes studies often take 3 to 5 years and can cost tens to hundreds of millions of dollars. With a lean structure and focused capital use, Amarin Corporation plc can keep evidence generation tight, which makes imitation slow, costly, and uncertain.
Organization
Amarin Corporation plc’s organization supports focused capital allocation by keeping a lean operating model while maintaining the regulatory and compliance systems needed to sell in multiple jurisdictions. That structure matters for a company with 2025 net revenue of about $200 million and ongoing cross-border oversight for prescription cardiovascular medicines.
Competitive Advantage
Amarin Corporation plc’s focused capital allocation and lean operating model support competitive parity, not a durable VRIO edge. In FY2025, the business stayed tightly cost-controlled, but lower spending mainly helped preserve cash and absorb revenue pressure rather than create a harder-to-copy advantage.
Amarin Stays Lean: VASCEPA Drives Revenue, Not a Wide Moat
Amarin Corporation plc keeps capital tightly aimed at VASCEPA promotion and compliance, so FY2025 spend stayed lean versus larger drug peers. With about $200 million of net revenue in 2025 and a narrow operating base, the model supports cash control and fast channel support, but it does not create a hard-to-copy VRIO edge.
| FY2025 metric | Value |
|---|---|
| Net revenue | about $200 million |
| Model | single-asset, lean cost base |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.